Cellular Biomedicine Group to Present at New York Stem Cell Summit

Cellular Biomedicine Group to Present at New York Stem Cell Summit

PALO ALTO, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group
Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new
treatments for degenerative and cancerous diseases, today announced that Dr.
Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th
annual New York Stem Cell Summit. More than 30 of the world's leaders in this
rapidly evolving industry will meet on February 18, 2014 at The Convene in New
York City to discuss the global stem cell industry outlook and forecast.

Dr. Cao will speak during the segment, "Practical Methods for Combining Cells
and Tissue Engineering". His presentation is titled "Study of Adipose Derived
Mesenchymal Precursor Cells Therapy; Re-Join^TM for Osteoarthritis".

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental stem
cell, progenitor cell, and immune cell projects are the result of research and
development by scientists and doctors fromChinaandthe United States. Our
flagship GMP facility, consisting of eight independent cell production lines,
is designed, certified and managed according to U.S. standards. To learn more
about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         Christopher Chu
         Director Investor Relations, Grayling
         +1 646 284-9426

Cellular Biomedicine Group Inc. Logo
Press spacebar to pause and continue. Press esc to stop.